Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Cancer Immunol Res. 2016 May 13;4(7):569–573. doi: 10.1158/2326-6066.CIR-15-0281

Figure 1.

Figure 1

Figure 1A: Progression free survival to pembrolizumab in patients with ≥ 90 day PFS vs patients with < 90 day PFS to ipilimumab, (237 days vs 125 days, P = 0.09).

Figure 1B: Overall survival to pembrolizumab in patients with ≥ 90 day PFS vs patients with < 90 day PFS to ipilimumab, (374 days vs 282 days, P = 0.06)